In this article, we will discuss Durvalumab (Warnings-12). So, let’s get started.
Immune-mediated colitis occurred in 2% (37/1889) of patients receiving Durvalumab, including Grade 4 (<0.1%) and Grade 3 (0.4%) adverse reactions. Events resolved in 27 of the 37 patients and resulted in permanent discontinuation in 8 patients. Systemic corticosteroids were required in all patients with immune-mediated colitis, while 2 patients (2/37) required other immunosuppressants (e.g. infliximab, mycophenolate).